News Headlines

  1. Fosun Pharma's Subsidiary Yao Pharma And Pfizer Enter Into Exclusive Collaboration And License Agreement 12/9/2025

    Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement.

  2. uBriGene Biosciences And Circurna Announce Strategic Partnership To Accelerate Development And Manufacturing Of Circular RNA/LNP Therapeutics 12/9/2025

    uBriGene Biosciences, a global CDMO specializing in Advanced Therapy Medicinal Product (ATMP) GMP development and manufacturing, today announced a strategic partnership with Circurna, a biotechnology company pioneering next-generation circular RNA (circRNA) therapeutics.

  3. Akadeum Life Sciences Announces Establishment Of The Akadeum CDMO Alliance Program 12/9/2025

    Akadeum Life Sciences, the leader in buoyant cell separation, announces the establishment of the Akadeum CDMO Alliance™ and the first two members in the consortium.

  4. Grace and Molecule.one To Transform Peptide Building Block Synthesis With AI And Automation 12/8/2025

    The two companies enter into a multi-year strategic agreement to accelerate drug development timelines, strengthen U.S. manufacturing capabilities and help bring lifesaving medicines to patients faster.

  5. SeaBeLife Enters Into Joint Development Agreement With Unither Pharmaceuticals To Formulate And Produce Ophthalmic Drug Candidate 12/8/2025

    SeaBeLife, a biotechnology company developing innovative drug candidates intended to block cellular necrosis, today announces it has signed a joint development agreement with Unither Pharmaceuticals, a French pharmaceutical CDMO with an international footprint, specialized in the development and manufacture of sterile single doses.

  6. Andelyn Biosciences Announces Partnership With Jaguar Gene Therapy To Provide Late-Stage PPQ Manufacturing 12/8/2025

    Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Jaguar Gene Therapy to perform late-stage Process Performance Qualification (PPQ) manufacturing of JAG201, an investigational gene therapy targeting SHANK3 haploinsufficiency which is clinically diagnosed as Phelan-McDermid syndrome (PMS), a leading monogenic cause of autism spectrum disorder (ASD).

  7. GlycoNex Signs CDMO Service Agreement With Change Cure To Advance HMGB1-Targeted Antibody Program 12/8/2025

    GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a CDMO service agreement with the Institute of Science Tokyo (Science Tokyo) and Change Cure Co., a biotechnology company spun out from Science Tokyo.

  8. AsymBio Commences Commercial Operations At Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities 12/8/2025

    AsymBio, a technology-driven global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), today announced the official start of commercial production at its Shanghai Fengxian Commercial Manufacturing Base.

  9. Bora Pharmaceuticals Marks Five Years In Mississauga, Canada, Strengthening Its Commitment To Onshore And Global CDMO Excellence 12/5/2025

    Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today celebrates the five-year anniversary of its Mississauga, Ontario, Canada facility, a key hub in the company’s North American operations and a cornerstone of its expanding international CDMO network. The milestone will be celebrated onsite with employees, partners, and community stakeholders.

  10. Quotient Sciences And Intrepid Labs Form Strategic Partnership To Accelerate AI-Guided Formulation Development 12/4/2025

    Under the new agreement, Quotient Sciences will have access to Intrepid’s machine learning model, ANDROMEDA, the first AI platform to develop and optimize clinical performance of drug products. The platform is designed to significantly reduce formulation development timelines, reduce API demands and increase formulation understanding, helping clients reach critical milestones faster and improve confidence in clinical success.